Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a controlled clinical trial.

Many studies conducted in the last two decades have aroused interest in the role of glomerular hyperfiltration in the pathogenesis of renal damage in hypertension.

Who Took Part

The abstract describes 32 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Before and after active treatment the following parameters were assessed: blood pressure (mercury sphygmomanometry), glomerular filtration rate (GFR), renal plasma flow, and lithium clearance (clearances of inulin, PAH and orally administered lithium, respectively), plasma ANP (radioimmunoassay), and, only at baseline, plasma renin activity, plasma and urinary aldosterone (radioimmunoassay) and NLE (sodium stimulated lithium efflux).

How the Study Was Run

The researchers set it up as an open-label and placebo-controlled study.

Being open-label, the ANP (Atrial Natriuretic Peptide) study did not mask who received what.

Some patients received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Angiotensin-Converting Enzyme Inhibitors, Atrial Natriuretic Factor, Blood Pressure Determination, Glomerular Filtration Rate, Hypertension, Kidney Function Tests and Natriuresis.

What This Means in Plain Language

The paper is an open-label and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 32 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Journal of nephrology), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.